Turna Ray

After the VALID Act didn't pass, it's uncertain how the FDA will proceed, though some payors aren't waiting for the status quo to change and asking labs to submit additional validation data on cancer tests.

During the third quarter, the company saw 24 percent revenue growth from the year-ago period, but the company lowered its full-year expectations.

The company, infamous and long derided in the genetic testing community for refusing to share BRCA1/2 variants, has decided to change its stance as part of a "strategic transformation."

If the Center for Genomic Interpretation's in silico quality assessment catches on with payors, some labs are sure to push back or propose data sharing as an alternative.

The payor wants to see data beyond what is required through CLIA, and recommends labs use the Center for Genomic Interpretation to gauge how well tests detect and interpret variants.

Several institutions, swayed by PGx experts and advocates, are setting up DPYD testing to avoid deadly chemo toxicities in patients even though the NCCN and FDA don't back it. 

The company is offering combined germline and somatic cancer testing, and sharing patients' variants identified through that testing in a new research registry.

The Right Drug Dose Now Act seeks to address many of the barriers that have hindered integration of pharmacogenomic information into mainstream care.

The company believes the platform will expedite its longstanding goal of amassing genomic and other information from patients through their lifespan to fuel discoveries and improve care.

The company plans to launch a polygenic risk score, a germline-somatic test platform, and LDT and kitted tests for disease monitoring and therapy selection.